| 词条 | Floxuridine | ||||||||||
| 释义 |
| verifiedrevid = 461100974 | IUPAC_name = 5-Fluoro-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-pyrimidine-2,4-dione | image = Floxuridine.png | tradename = | Drugs.com = {{drugs.com|monograph|floxuridine}} | MedlinePlus = a682006 | pregnancy_US = D | legal_status = | routes_of_administration = Intra-arterial | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | IUPHAR_ligand = 4801 | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 50-91-9 | ATC_prefix = L01 | ATC_suffix = BC09 | ATC_supplemental = | PubChem = 5790 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB00322 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 5586 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 039LU44I5M | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D04197 | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = 60761 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 917 | C=9 | H=11 | F=1 | N=2 | O=5 | melting_point = 150.5 | smiles = FC=1C(=O)NC(=O)N(C=1)[C@@H]2O[C@@H]([C@@H](O)C2)CO | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C9H11FN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = ODKNJVUHOIMIIZ-RRKCRQDMSA-N }}Floxuridine (also 5-fluorodeoxyuridine) is an oncology drug that belongs to the class known as antimetabolites. Specifically, floxuridine is a pyrimidine analog, classified as a deoxyuridine.[1] The drug is usually administered via an artery, and most often used in the treatment of colorectal cancer. The quality of life and survival rates of individuals that receive continuous hepatic artery infusion of floxuridine for colorectal cancer metastases is significantly higher than control groups.[2] Floxuridine can also be prescribed for the treatment of kidney and stomach cancers.[3] In vitro uses of floxuridine include 5-minute treatments of fluorouracil, floxuridine, and mitomycin to increase cell proliferation in Tenon's capsule fibroblasts.[4] BiosynthesisImmobilized Aeromonas salmonicida ATCC 27013, when exposed to thymidine and 5-fluorouracil in phosphate buffer at room temperature for one hour, can synthesize floxuridine and thymine.[5] Pharmacology[6]Floxuridine primarily works by stopping the growth of newly born cells. The drug essentially stops DNA from forming in new and rapidly developing cells, which is a sign of a cancerous cell. Therefore, the floxuridine kills the cancerous cells. For colorectal cancer and hepatic metastases, an average adult should be given an Intra-arterial dosage of 0.1–0.6 mg/kg/day as a continuous infusion, continued until intolerable toxicity is reached (white blood cell count <3,500/mm^3 or platelet count <100,000/mm^3).[7] Lethal dosages for other species are below.[8] LD50 is the lethal dose at which half of organisms exposed to the drug die.
PharmacodynamicsFloxuridine is a pyrimidine analog that acts as an inhibitor of the S-phase of cell division. This selectively kills rapidly dividing cells. Antimetabolites masquerade as pyrimidine-like molecules which prevents normal pyrimidines from being incorporated into DNA during the S phase of the cell cycle. Fluorouracil (the end-product of catabolism of floxuridine) blocks an enzyme which converts cytosine nucleosides into the deoxy derivative. In addition, DNA synthesis is further inhibited because fluoruracil blocks the incorporation of the thymidine nucleotide into the DNA strand. Mechanism of actionFloxuridine is rapidly catabolized to 5-fluorouracil, which is the active form of the drug. The primary effect is interference with DNA synthesis and to a lesser extent, inhibition of RNA formation through the drug's incorporation into RNA, thus leading to the production of fraudulent RNA. Fluorouracil also inhibits uracil riboside phosphorylase, which prevents the utilization of preformed uracil in RNA synthesis. As well, the monophosphate of floxuridine, 5-fluoro-2'-deoxyuridine-5'-phosphate (FUDR-MP) inhibits the enzyme thymidylate synthetase. This leads to the inhibition of methylation of deoxyuridylic acid to thymidylic acid, thus interfering with DNA synthesis. Route of EliminationThe drug is excreted intact and as urea, fluorouracil, α-fluoro-β-ureidopropionic acid, dihydrofluorouracil, α-fluoro-β-guanidopropionic acid and α-fluoro-β-alanine in the urine; it is also expired as respiratory carbon dioxide. Side effectsSide effects include:[9] Common (30% of patients)
Less common (10–29% of patients)
Contact your health provider immediately
Contact your health provider
Other
HistoryFloxuridine first gained FDA approval in December 1970 under the brand name FUDR. The drug was initially marketed by Roche, which also did a lot of the initial work on 5-fluorouracil. The National Cancer Institute was an early developer of the drug. Roche sold its FUDR product line in 2001 to F H Faulding, which became Mayne Pharma. Alternative namesSynonyms for floxuridine include:[10] {{col-begin|width=auto}}{{col-break}}
References1. ^{{cite web|title=Floxuridine|url=https://pubchem.ncbi.nlm.nih.gov/compound/floxuridine#section=Top|website=PubChem|accessdate=18 April 2017}} {{Chemotherapeutic agents}}2. ^{{cite journal|last1=Allen-Mersh|first1=TG|last2=Earlam|first2=S|last3=Fordy|first3=C|last4=Abrams|first4=K|last5=Houghton|first5=J|title=Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases|journal=The Lancet|date=November 1994|volume=344|issue=8932|pages=1255–1260|doi=10.1016/S0140-6736(94)90750-1|url=http://www.sciencedirect.com/science/article/pii/S0140673694907501}} 3. ^{{cite web|title=Floxuridine|url=http://chemocare.com/chemotherapy/drug-info/floxuridine.aspx|website=Chemocare|publisher=Chemocare.com|accessdate=17 April 2017}} 4. ^{{cite journal|last1=Khaw|first1=Peng T.|last2=Sherwood|first2=Mark B.|last3=Mackay|first3=Sally L. D.|title=Five-Minute Treatments With Fluorouracil, Floxuridine, and Mitomycin Have Long-term Effects on Human Tenon's Capsule Fibroblasts|journal=JAMA Ophthalmology|volume=110|issue=8|pages=1150|date=August 1992|doi=10.1001/archopht.1992.01080200130040|url=http://jamanetwork.com/journals/jamaophthalmology/article-abstract/639809|accessdate=7 May 2017}} 5. ^{{cite journal|last1=Rivero|first1=Cintia|last2=Britos|first2=Claudia|last3=Mario|first3=Lozano|last4=Sinisterra|first4=Jose|last5=Trelles|first5=Jorge|title=Green biosynthesis of floxuridine by immobilized microorganisms|journal=FEMS Microbiology Letters|volume=331|date=March 12, 2012|issue=331|pages=31–36|doi=10.1111/j.1574-6968.2012.02547.x}} 6. ^{{cite web|last1=Canadian Institutes of Health Research|title=Floxuridine|url=https://www.drugbank.ca/drugs/DB00322|website=DrugBank|accessdate=18 April 2017}} 7. ^{{cite web|title=Floxuridine|url=https://www.drugs.com/ppa/floxuridine.html|website=Drugs.com}} 8. ^{{cite web|title=Floxuridine|url=https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=134053|publisher=Bedford Laboratories}} 9. ^{{cite web|title=Floxuridine|url=http://chemocare.com/chemotherapy/drug-info/floxuridine.aspx|website=Chemocare|publisher=Chemocare.com|accessdate=17 April 2017}} 10. ^{{cite web|last1=Canadian Institutes of Health Research|title=Floxuridine|url=https://www.drugbank.ca/drugs/DB00322|website=DrugBank|accessdate=18 April 2017}} 4 : Pyrimidine antagonists|Nucleosides|Organofluorides|Pyrimidones |
||||||||||
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。